India's Lupin clears patent hurdle with Astellas Pharma, keeps Mirabegron sales in US
Indian drugmaker Lupin has settled a patent infringement dispute with Astellas Pharma regarding the bladder drug Mirabegron, allowing continued sales in the U.S. Lupin will pay Astellas $90 million, including a $75 million upfront payment and licensing fees until September 2027. This agreement resolves ongoing litigation and permits Lupin to market its generic version of Myrbetriq in the U.S.
Source: marketscreener The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments